Abstract: A nutrient carrier comprises a body which is particularly suited for delivering nutrients via the oral cavity and pharynx. The body of the nutrient carrier comprises or includes a nutrient carrier element or material/composition. For example, the nutrient carrier body may be constructed from a nutrient carrying composition. In other embodiments, the nutrient carrier body may be constructed from a carrier material which carries a desired nutrient (such as a supplement, vitamin, mineral or medication/drug).

Abstract: Disclosed is a construct comprising a virus coat protein usable as a carrier for drug delivery adaptable to various drugs. Specifically disclosed is a construct coated with a virus coat protein, comprising a virus coat protein and a construct coated therewith, wherein the virus coat protein is attached to the surface of the construct to form a layer of the protein thereon.

Abstract: This disclosure relates to particles (e.g., nanoparticles and microparticles) that display multiple functionalized surface domains in a controlled mosaic pattern. The disclosure also provides simple methods to create various particles that have multiple functionalized surface domains while allowing the use of a wide variety of diverse core structures. The multiple functionalized domains provide controllable particle binding and orientation, and controlled and sustained drug release profiles.

Abstract: The disclosure provides methods for increasing genome stability of an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell, increasing telomere length in an ES or iPS cell, or both, for example by contacting an ES or iPS cell with an agent that increases expression of Zscan4 in the cell. Methods for increasing the genome stability in a population of ES or iPS cells, increasing telomere length in a population of ES or iPS cells, or both, are provided, for example by selecting Zscan4+ ES or iPS cells from the population of ES or iPS cells (which can include both Zscan4+ and Zscan4? ES or iPS cells). Therapeutic methods of using ES or iPS cells expressing Zscan4 are also provided. Further provided are methods of treating cancer by administering a Zscan4 polynucleotide or Zscan4 polypeptide. Also provided are methods of inducing differentiation of isolated ES or iPS cells into germ cells.

Abstract: The present invention relates to novel nanoparticles formed by at least one active ingredient and by at least two polyelectrolytes of opposite polarity, in particular characterized in that at least one of the two polyelectrolytes bears hydrophobic side groups and at least one of the two polyelectrolytes bears side groups of the polyalkylene glycol type, said nanoparticles having an average diameter ranging from 10 to 100 nm and comprising a quantity of groups of the polyalkylene glycol type such that the mass ratio wPAG of polyalkylene glycol relative to the total polymer is greater than or equal to 0.05.

Abstract: The present invention provides a variety of nucleic acid based therapeutics and methods of use thereof which are effective to beneficially reprogram diseased cells such that they exhibit more desirable phenotypes. Also provided are compositions and methods to reprogram normal cells for medical and commercial purposes.

Abstract: A polymer capsule manufactured by polymerizing a compound represented by Formula 1, or polymerizing the compound of Formula 1 and a compound of Formula 2, wherein a detailed structure of the compounds of Formulae 1 and 2 is presented in the detailed description.

Abstract: The present invention relates to a liquid lipid core/solid lipid shell capsule surface-functionalized with at least one compound containing at least one amino function, characterized in that the lipid core/lipid shell architecture is on the nanometric scale and in that said compound is covalently bonded to said solid lipid shell via a transacylation reaction. It also relates to a method for preparing such capsules.

Abstract: The invention relates to composite materials comprising polymer nanofibers and polymer nanoparticles, wherein at least one of the two polymer materials is loaded with a substance selected from therapeutic and diagnostic agents. Fibers and nanoparticles can comprise identical or different polymers; the polymer materials are, however, biocompatible in every case. Therapeutic and diagnostic agents can be hydrophilic or lipophilic and the two polymer materials likewise. The at least one polymer material and the substance with which said material is loaded are either both hydrophilic or both lipophilic. The polymer nanoparticles of the composite materials have a diameter of 10 nm to 600 nm. The polymer fibers have diameters of 10 nm to 50 ?m and lengths of 1 ?m to several meters. The invention further relates to a method for producing said composite materials.

Abstract: An article comprising a polyelectrolyte complex comprising an interpenetrating network of at least one predominantly positively charged polyelectrolyte polymer and at least one predominantly negatively charged polyelectrolyte polymer, the polyelectrolyte complex further comprising a plurality of closed-shell pores, the plurality of pores having at least one average transverse dimension between about 100 nanometer and about 1000 micrometers.

Abstract: The invention discloses novel morphology shifting micelles and amphiphilic coated metal nanofibers. Methods of using and making the same are also disclosed.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.

Abstract: Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning.

Abstract: The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.

Abstract: System and method for loading the front line anticancer drug, doxorubicin (DOX) onto DNA-capped gold nanoparticles whose duplex DNA has been designed for specific DOX intercalation. Since each AuNP contains about 108 high affinity drug sites, this design allows for a high local DOX concentration on the particle. Drug binding was confirmed by monitoring the increase in DNA melting temperature, the shift in the plasmon resonance maximum, and the increase in the NP hydrodynamic radius as a function of [DOX]/[DNA] ratio. The feasibility of the nanoparticles as a drug delivery system was demonstrated by showing that particle-bound DOX could be transferred to a target DNA.

Abstract: A delivery device for an active agent comprises nanoparticles based on a biopolymer such as starch. The delivery device may also be in the form of an aptamer-biopolymer-active agent conjugate wherein the aptamer targets the device for the treatment of specific disorders. The nanoparticles may be made by applying a high shear force in the presence of a crosslinker. The particles may be predominantly in the range of 50-150 nm and form a colloidal dispersion of crosslinked hydrogel particles in water. The biopolymer may be functionalized. The aptamer may be conjugated directly to the cross-linked biopolymers. The active agent may be a drug useful for the treatment of cancer. The delivery device survives for a period of time in the body sufficient to allow for the sustained release of a drug and for the transportation and uptake of the conjugate into targeted cells. However, the biopolymer is biocompatible and resorbable.

Abstract: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.

Abstract: The present invention provides methods and compositions for the stimulation of immune responses. Specifically, the present invention provides methods and compositions for the use of nanoemulsion compounds as mucosal adjuvants to induce immunity against environmental pathogens. Accordingly, in some embodiments, the present invention provides nanoemulsion vaccines comprising a nanoemulsion and an inactivated pathogen or protein derived from the pathogen. The present invention thus provides improved vaccines against a variety of environmental and human-released pathogens.

Abstract: A targeted drug delivery nanocarrier and a method of forming the same is disclosed herein. The targeted drug delivery nanocarrier includes a plurality of amphipathic molecules forming a carrier particle having a plurality of drug molecules contained therein. A targeted landscape phage protein assembly is complexed to the carrier particle preferably using the unique method disclosed herein. The targeted landscape phage protein assembly displays a binding peptide that is selected to specifically and selectively bind to a target site. The method for forming targeted drug delivery nanocarriers includes the steps of obtaining a plurality of bacteriophage displaying a binding peptide for a desired target site, treating the bacteriophage with a denaturing agent, mixing the treated bacteriophage with a plurality of carrier particles and purifying the mixture to obtain a plurality of targeted drug delivery nanocarriers.

Abstract: Cationic poly(ester ether amide)s (PEEAs) and compositions comprising PEEAs and biomolecules such as nucleic acids and proteins. Also, a method for intracellular delivery of biomolecules using complexes of the PEEAs and biomolecules. For example, PEEAs can be used as transfection agents for nucleic acids such as DNA and RNA.

Abstract: An object of the present invention is to provide a uronic acid-containing glucan or a modified product thereof. The glucuronic acid-containing glucan of the present invention is a glucuronic acid-containing glucan in which a glucuronic acid residue is bound to at least one non-reducing end of a glucan, and the glucan is a branched ?-1,4 glucan or a linear ?-1,4 glucan. The glucuronic acid-containing glucan of the present invention can be provided by allowing ?-glucan phosphorylase derived from Aquifex aeolicus VF5 to act on glucuronic acid-1-phosphate to thereby transfer a glucuronic acid residue to the non-reducing end of the receptor glucan.

Abstract: The present invention provides methods and devices for the fabrication of 3D polymeric fibers having micron, sub-micron, and nanometer dimensions, as well as methods of use of these polymeric fibers.

Abstract: The invention provides process for making water-soluble nano-dispersions of water-insoluble materials in a water-soluble carrier material comprising the steps of: (i) providing a single phase mixture of: (a) a non-aqueous solvent or a mixture of miscible non-aqueous solvents, (b) at least one carrier material soluble in non-aqueous solvent (a), said carrier material being also soluble in water and solid at ambient temperature, (c) at least one water-insoluble payload material which is soluble in non-solvent (a), and, (ii) drying the mixture to remove solvent (a) and thereby obtain the carrier material (b) in solid form with payload (c) dispersed therein as nanoparticles, wherein the product of the drying step is water dispersible to give an aqueous solution of (b) and an aqueous nano-dispersion of (c).

Abstract: The invention relates generally to a medical device, such as an intravascular stent, for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. More particularly, the invention pertains to a medical device having a metal oxide or metal material with a plurality of pores therein disposed on the surface of the medical device and a polymer disposed on the metal oxide or metal material. The invention also relates to medical devices having a surface and an outer region comprising a metal oxide or metal material having a plurality of pores therein and a polymer disposed on the metal oxide or metal material.

Abstract: The present invention provides novel calcium phosphate nanoparticles suitable for efficient encapsulation of biologically active molecules. The invention further provides pharmaceutical compositions comprising these nanoparticles, as well as methods of making such nanoparticles and using them as carriers for therapeutic delivery of biologically active macromolecules.

Abstract: The present invention relates to oligomeric or polymeric saccharide derivatives comprising glucosamine moieties, e.g. derivatives of oligomeric or polymeric glucosamines such as chitosan oligomers or polymers, in which one or more amine groups are substituted by anchoring groups that chemisorb to the surface of a nanoparticle or form an interdigitated bilayer with a surfactant layer surrounding the nanoparticle. The invention also relates to functionalized nanoparticles comprising such derivatives, a method for forming the functionalized particles and to uses thereof as molecular imaging agents, biosensing agents or drug delivery agents, or in the preparation of such agents.

Abstract: A composition comprising nanoparticles of a hydrolysable silicon-contain material for use as a delivery system for a bioactive ingredient, wherein surface of the silicon-containing material is associated with a stabilizing agent which modifies the rate of hydrolysis of the silicon-contain material and/or inhibits the rate of orthosilicic acid polymerisation and a method of promoting the controlled release of orthosilicic acid on degradation of a composition comprising nanoparticles of a hydrolysable silicon-contain material, the method involving the treatment of the surface of the silicon-containing material with a stabilizing agent to modify the rate of hydrolysis of the silicon-containing material and/or inhibit the rate of orthosilicic acid polymerisation.

Abstract: The present invention provides combination therapy methods of treating a proliferative disease (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include the administration of an effective amount of at least one other agent that inhibits a pro survival and/or inflammatory signal.

Abstract: The invention provides a biocompatible carrier and method for fabricating the same. The biocompatible carrier includes: a gel, and a plurality of metal nanoparticles, an organic compound or combinations thereof embedded in the gel, wherein the metal nanoparticles, the organic compound or combinations thereof are uniformly distributed in the gel.

Abstract: Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.

Abstract: Disclosed are: a composition which enables the more effective development of the efficacy of a water-soluble drug in a solution containing the drug; and a dispersion in which a hydrophobic drug can be dispersed stably without requiring the use of any surfactant. Specifically disclosed are: a composition comprising ultra-fine bubbles having a mode particle size of 500 nm or less, a drug and water; and a process for producing a composition comprising ultra-fine bubbles having a mode particle size of 500 nm or less, a drug and water, which utilizes an ultra-fine bubble generation apparatus.

Abstract: The present invention relates to a method for inhibiting reperfusion injury in the brain. The method involve injecting via the carotid artery or jugular vein an antioxidant-loaded nanoparticle. A nanoparticle formulation containing an inert plasticizer is also provided for sustained release of an active agent.

Abstract: The present invention relates to a system for administering active ingredients comprising nanocapsules with a diameter less than 1 ?m comprising a polyarginine salt, a negative phospholipid and an oil. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical and cosmetic compositions thereof, as well as the use thereof in medicine, particularly in the preparation of a drug for treating cancer.

Abstract: The present disclosure describes environmentally responsive polypeptides capable of displaying stimuli-triggered conformational changes in a reversible or irreversible manner that may be accompanied by aggregation. Polypeptides include a number of repeated motifs and may be elastomeric or non-elastomeric. The polypeptides may be used to deliver therapeutics to a biological site and to develop bioactive polypeptides that are environmentally responsive.

Abstract: A nanosphere or microsphere drug carrier, formulations comprising the drug carrier and the preparation method of the formulations and the use of the carrier are disclosed. The carrier comprises a biodegradable methoxy end-capped polyethylene glycol-polylactide block copolymersor a derivative thereof represented by formula (I) as the main carrier material: CH3O—[CH2—CH2—O]m—[C(O)—CH(CH3)—O]n—R (I).

Abstract: Multifunctional nanoparticles for imaging and therapeutic drug delivery made from amphiphilic block copolymers having a hydrophobic block and one or more hydrophilic blocks, and at least one internal and one terminal chelating agent units having a paramagnetic metal ion associated therewith.

Abstract: The invention relates to an emulsion that can be activated by ultrasounds, comprising, in an emulsion in an aqueous solution, microparticles having a diameter of less than 10 ?m and containing an active agent and a gaseous precursor in a liquid form, encapsulated by a first emulsifier. The microparticles contain nanoparticles smaller than 1 ?m, in an emulsion in the gaseous precursor, each nanoparticle comprising an inner liquid that contains the active agent and is encapsulated by a second emulsifier.

Abstract: The present invention is directed to mometasone furoate compositions comprising mometasone furoate and at least one surface stabilizer. The mometasone furoate particles of the composition preferably have an effective average particle size of less than about 2000 nm.

Abstract: Method of making particle compositions exhibiting improved floodability and/or flowability properties. The compositions generally contain particles and non-surface modified nanoparticles.

Abstract: A method of preparing antimicrobial-containing polymeric products is provided, the method involving electrospinning a dispersion comprising a dispersible polymer, a fiberizing polymer, and one or more antimicrobial agents. The electrospun material is heated to remove solvent and the fiberizing polymer, giving a nonwoven polymeric material having antimicrobial agent incorporated therein. The material can be in the form of, for example, a non-woven sheet, tube, or covering.

Abstract: A process for the preparation of a polymer nanoparticle by a photoinduced emulsion polymerization includes preparing an emulsion comprising at least one surfactant, a dispersed phase and a continuous phase. The dispersed phase comprises at least one polymerizable monomer and the continuous phase comprises water and at least one photoinitiator. The at least one polymerizable monomer is polymerized by exposing the emulsion to an electromagnetic radiation having a wavelength so as to induce a generation of radicals from the at least one photoinitiator.

Abstract: Compositions including a surface or film comprising nanofibers, nanotubes or microwells comprising a bioactive agent for elution to the surrounding tissue upon placement of the composition in a subject are disclosed The compositions are useful in medical implants and methods of treating a patient in need of an implant, including orthopedic implants, dental implants, cardiovascular implants, neurological implants, neurovascular implants, gastrointestinal implants, muscular implants, and ocular implants.

Abstract: An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided.

Abstract: Provided herein are compounds and related composition and methods that may be used to raise an antibody response to nicotinic compounds, in some embodiments.

Abstract: The present invention includes fullerene carbon nanotube compositions complexed with multiple bioactive agents and methods related to such fullerene carbon nanotube compositions.

Abstract: A method for treating or ameliorating mucocutaneous, ocular toxicities, or side effects induced by blocking cellular growth and survival signal transduction pathways. The method comprises administering to a subject in need thereof an effective amount of a histone deacetylase inhibitor and a pharmaceutically acceptable carrier, salt or solvate thereof, wherein the cell growth and survival signal transduction pathways are blocked by an antibody targeted therapy agent, antibody fragment, targeted small-molecule chemical compound, low-molecular-weight tyrosine kinase inhibitor, peptide mimetic, anti-sense oligonucleotide (DNA and/or RNA), or ribozyme.

Abstract: Methods and compositions for treating cancer and other disorders by ?-endorphin therapy are disclosed.

Abstract: Methods and compositions related polymers and hydrogels. In some cases to biodegradable hydrogels for use in medical applications are disclosed. The polymers and hydrogels may be produced from cross-linked dextran and poly(epoxides). The poly(epoxides) may be poloxamers.

Abstract: Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.

Abstract: Provided are an siRNA-polymer conjugate, and a method for preparing the same, and more specifically, to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the present invention can improve the in vivo stability of siRNA, thereby achieving an efficient delivery of therapeutic siRNA into cells and exhibiting the activity of siRNA even with a small dose of a relative low concentration. Therefore, the conjugate can advantageously be used as not only an siRNA treatment tool for cancers and other infectious disease, but also a novel type siRNA delivery system.